Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Big Pharma and Orphan Drugs: The Case for Thinking Small

This article was originally published in RPM Report

Executive Summary

In this issue, The RPM Report looks at three advocates making three different but inter-related cases for greater involvement by Biopharma companies in research into rare diseases. Do they have any takers?

You may also be interested in...



FDA Looking To Patient Advocates To Answer Benefit-Risk Questions

FDA’s clinical review teams are starting to approve novel drugs and biologics using a new structured benefit-risk framework developed under PDUFA V. Those assessments ask reviewers to think more broadly about the disease and how a new treatment might fit into the current treatment model. But many reviewers don’t have that information. And that, FDA says, is where patient advocates come in.

Valuing Genzyme: A Health Care Reform Premium

Sanofi has gone public with an $18.5 billion bid for Genzyme, but investors assume the French company is willing to go higher. So the question everyone is asking is, How much is Genzyme worth? The answer should include a premium for the special treatment the company will get under the health care reform law in the US.

Valuing Genzyme: A Health Care Reform Premium

Sanofi has gone public with an $18.5 billion bid for Genzyme, but investors assume the French company is willing to go higher. So the question everyone is asking is, How much is Genzyme worth? The answer should include a premium for the special treatment the company will get under the health care reform law in the US.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS080519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel